Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Natera鈥檚 genomic jargon isn鈥檛 easy. Each 10-K details everything from cfDNA assay accuracy to payer reimbursement disputes, while 8-K updates often cover fast-moving clinical-trial milestones. If you鈥檝e ever wondered how to locate test-volume data, or needed Natera insider trading Form 4 transactions before the market reacts, you know the challenge.
Stock Titan solves it. Our AI reads every Natera quarterly earnings report 10-Q filing, highlights revenue per test, and translates accounting footnotes into plain language. AG真人官方-time alerts flag Natera Form 4 insider transactions real-time, so you can track executive stock moves the moment they hit EDGAR. Need the full picture? We link each 10-K, 10-Q, 8-K, proxy DEF 14A, and S-8 in one place鈥�Natera SEC filings explained simply. Common questions such as 鈥淗ow do I find the latest Natera proxy statement executive compensation?鈥� or 鈥淲here is the Natera 8-K material events explained?鈥� are answered inside every filing card.
Our platform doesn鈥檛 stop at document delivery. AI-powered summaries spotlight what matters for a diagnostics company: R&D spend versus cash on hand, progress of the Signatera oncology pipeline, and changes in CMS reimbursement that can swing margins. Use cases include:
- Compare quarter-over-quarter test volumes without sifting through tables
- Monitor Natera executive stock transactions Form 4 for buying or selling trends
- Assess dilution risk by reviewing shelf registrations and ATM offerings
- Download an Natera annual report 10-K simplified PDF automatically annotated by AI
- Receive instant alerts when a new Natera earnings report filing analysis is available
- Get guidance on understanding Natera SEC documents with AI-generated glossaries
Whether you鈥檙e a healthcare analyst, portfolio manager, or clinician-investor, Stock Titan turns Natera鈥檚 dense disclosures into actionable insight鈥攏o genetics PhD required.
Natera, Inc. (NTRA) 鈥� Form 4 insider activity filed 07/03/2025
Director Gail Marcus Boxer exercised 4,299 stock-option shares at an exercise price of $24.42 on 07/01/2025 (Code M). The same day, she sold the entire 4,299 shares in two open-market blocks under a pre-arranged Rule 10b5-1 plan adopted 12/11/2024:
- 1,648 shares at a weighted-average price of $167.0518 (range $166.2989鈥�$167.2833)
- 2,651 shares at a weighted-average price of $167.5554 (range $167.30鈥�$168.0343)
Gross proceeds approximate $718 k, implying a spread of roughly $142.6 per share versus the $24.42 strike. Following the transactions, Boxer's direct ownership declines to 8,118 common shares, down from 12,417 immediately after the option exercise. No derivative securities remain outstanding from the exercised grant (expiration 09/13/2028).
The trade represents a cashless, plan-based disposition and involves a modest share count relative to Natera鈥檚 >100 million shares outstanding, suggesting limited fundamental impact on the company鈥檚 capital structure. However, investors often monitor insider net selling for sentiment cues, even when conducted under 10b5-1 plans.
Natera, Inc. (NTRA) 鈥� Form 4 insider activity filed 07/03/2025
Director Gail Marcus Boxer exercised 4,299 stock-option shares at an exercise price of $24.42 on 07/01/2025 (Code M). The same day, she sold the entire 4,299 shares in two open-market blocks under a pre-arranged Rule 10b5-1 plan adopted 12/11/2024:
- 1,648 shares at a weighted-average price of $167.0518 (range $166.2989鈥�$167.2833)
- 2,651 shares at a weighted-average price of $167.5554 (range $167.30鈥�$168.0343)
Gross proceeds approximate $718 k, implying a spread of roughly $142.6 per share versus the $24.42 strike. Following the transactions, Boxer's direct ownership declines to 8,118 common shares, down from 12,417 immediately after the option exercise. No derivative securities remain outstanding from the exercised grant (expiration 09/13/2028).
The trade represents a cashless, plan-based disposition and involves a modest share count relative to Natera鈥檚 >100 million shares outstanding, suggesting limited fundamental impact on the company鈥檚 capital structure. However, investors often monitor insider net selling for sentiment cues, even when conducted under 10b5-1 plans.
Natera, Inc. (NTRA) 鈥� Form 4 insider activity filed 07/03/2025
Director Gail Marcus Boxer exercised 4,299 stock-option shares at an exercise price of $24.42 on 07/01/2025 (Code M). The same day, she sold the entire 4,299 shares in two open-market blocks under a pre-arranged Rule 10b5-1 plan adopted 12/11/2024:
- 1,648 shares at a weighted-average price of $167.0518 (range $166.2989鈥�$167.2833)
- 2,651 shares at a weighted-average price of $167.5554 (range $167.30鈥�$168.0343)
Gross proceeds approximate $718 k, implying a spread of roughly $142.6 per share versus the $24.42 strike. Following the transactions, Boxer's direct ownership declines to 8,118 common shares, down from 12,417 immediately after the option exercise. No derivative securities remain outstanding from the exercised grant (expiration 09/13/2028).
The trade represents a cashless, plan-based disposition and involves a modest share count relative to Natera鈥檚 >100 million shares outstanding, suggesting limited fundamental impact on the company鈥檚 capital structure. However, investors often monitor insider net selling for sentiment cues, even when conducted under 10b5-1 plans.
Natera, Inc. (NTRA) 鈥� Form 4 insider activity filed 07/03/2025
Director Gail Marcus Boxer exercised 4,299 stock-option shares at an exercise price of $24.42 on 07/01/2025 (Code M). The same day, she sold the entire 4,299 shares in two open-market blocks under a pre-arranged Rule 10b5-1 plan adopted 12/11/2024:
- 1,648 shares at a weighted-average price of $167.0518 (range $166.2989鈥�$167.2833)
- 2,651 shares at a weighted-average price of $167.5554 (range $167.30鈥�$168.0343)
Gross proceeds approximate $718 k, implying a spread of roughly $142.6 per share versus the $24.42 strike. Following the transactions, Boxer's direct ownership declines to 8,118 common shares, down from 12,417 immediately after the option exercise. No derivative securities remain outstanding from the exercised grant (expiration 09/13/2028).
The trade represents a cashless, plan-based disposition and involves a modest share count relative to Natera鈥檚 >100 million shares outstanding, suggesting limited fundamental impact on the company鈥檚 capital structure. However, investors often monitor insider net selling for sentiment cues, even when conducted under 10b5-1 plans.
Natera, Inc. (NTRA) 鈥� SEC Form 4 filing dated 07/01/2025
The filing reports two equity grants made on 06/27/2025 to director Roelof Botha.
- 2,143 Restricted Stock Units (RSUs) that vest in full on 06/12/2026 and accelerate upon a change in control.
- 271 RSUs with 25 % vesting immediately and the remaining 75 % vesting in three equal quarterly instalments.
Each RSU converts to one share of common stock. Following the transactions, Botha鈥檚 direct beneficial ownership rises to 6,517 shares. He also continues to hold 1,224,787 shares indirectly through estate-planning vehicles.
No open-market purchases or sales were reported; the transactions represent routine director compensation that increases share alignment without immediate cash outflow. There is no indication of derivative security activity beyond the RSUs disclosed.
Natera, Inc. (NTRA) 鈥� SEC Form 4 filing dated 07/01/2025
The filing reports two equity grants made on 06/27/2025 to director Roelof Botha.
- 2,143 Restricted Stock Units (RSUs) that vest in full on 06/12/2026 and accelerate upon a change in control.
- 271 RSUs with 25 % vesting immediately and the remaining 75 % vesting in three equal quarterly instalments.
Each RSU converts to one share of common stock. Following the transactions, Botha鈥檚 direct beneficial ownership rises to 6,517 shares. He also continues to hold 1,224,787 shares indirectly through estate-planning vehicles.
No open-market purchases or sales were reported; the transactions represent routine director compensation that increases share alignment without immediate cash outflow. There is no indication of derivative security activity beyond the RSUs disclosed.
Natera, Inc. (NTRA) 鈥� SEC Form 4 filing dated 07/01/2025
The filing reports two equity grants made on 06/27/2025 to director Roelof Botha.
- 2,143 Restricted Stock Units (RSUs) that vest in full on 06/12/2026 and accelerate upon a change in control.
- 271 RSUs with 25 % vesting immediately and the remaining 75 % vesting in three equal quarterly instalments.
Each RSU converts to one share of common stock. Following the transactions, Botha鈥檚 direct beneficial ownership rises to 6,517 shares. He also continues to hold 1,224,787 shares indirectly through estate-planning vehicles.
No open-market purchases or sales were reported; the transactions represent routine director compensation that increases share alignment without immediate cash outflow. There is no indication of derivative security activity beyond the RSUs disclosed.
Natera, Inc. (NTRA) 鈥� SEC Form 4 filing dated 07/01/2025
The filing reports two equity grants made on 06/27/2025 to director Roelof Botha.
- 2,143 Restricted Stock Units (RSUs) that vest in full on 06/12/2026 and accelerate upon a change in control.
- 271 RSUs with 25 % vesting immediately and the remaining 75 % vesting in three equal quarterly instalments.
Each RSU converts to one share of common stock. Following the transactions, Botha鈥檚 direct beneficial ownership rises to 6,517 shares. He also continues to hold 1,224,787 shares indirectly through estate-planning vehicles.
No open-market purchases or sales were reported; the transactions represent routine director compensation that increases share alignment without immediate cash outflow. There is no indication of derivative security activity beyond the RSUs disclosed.
Natera, Inc. (NTRA) 鈥� SEC Form 4 filing dated 07/01/2025
The filing reports two equity grants made on 06/27/2025 to director Roelof Botha.
- 2,143 Restricted Stock Units (RSUs) that vest in full on 06/12/2026 and accelerate upon a change in control.
- 271 RSUs with 25 % vesting immediately and the remaining 75 % vesting in three equal quarterly instalments.
Each RSU converts to one share of common stock. Following the transactions, Botha鈥檚 direct beneficial ownership rises to 6,517 shares. He also continues to hold 1,224,787 shares indirectly through estate-planning vehicles.
No open-market purchases or sales were reported; the transactions represent routine director compensation that increases share alignment without immediate cash outflow. There is no indication of derivative security activity beyond the RSUs disclosed.
Natera, Inc. (NTRA) 鈥� SEC Form 4 filing dated 07/01/2025
The filing reports two equity grants made on 06/27/2025 to director Roelof Botha.
- 2,143 Restricted Stock Units (RSUs) that vest in full on 06/12/2026 and accelerate upon a change in control.
- 271 RSUs with 25 % vesting immediately and the remaining 75 % vesting in three equal quarterly instalments.
Each RSU converts to one share of common stock. Following the transactions, Botha鈥檚 direct beneficial ownership rises to 6,517 shares. He also continues to hold 1,224,787 shares indirectly through estate-planning vehicles.
No open-market purchases or sales were reported; the transactions represent routine director compensation that increases share alignment without immediate cash outflow. There is no indication of derivative security activity beyond the RSUs disclosed.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
What core services does Natera Inc offer?
How does Natera ensure accuracy in its testing processes?
What is non-invasive prenatal testing (NIPT) and how does Natera apply it?
What role does bioinformatics play in Natera's diagnostic solutions?
How does Natera address the needs of oncology patients?
In what ways does Natera contribute to the field of genetic diagnostics?
How is Natera positioned within the competitive landscape of diagnostic companies?
